Protalix BioTherapeutics, Inc. (PLX)

Market Cap	94.13M
Revenue (ttm)	38.05M
Net Income (ttm)	-14.69M
Shares Out	73.54M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	3.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	969,124
Open	1.260
Previous Close	1.250
Day's Range	1.260 - 1.360
52-Week Range	0.820 - 1.900
Beta	0.67
Analysts	Strong Buy
Price Target	10.00 (+681.25%)
Earnings Date	Nov 12, 2024

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recomb...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 1998
• Employees: 208
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PLX
• Website: https://www.protalix.com

Analyst Forecast

According to one analyst, the rating for PLX stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(681.25% upside)

Analyst Consensus: Strong Buy